Reactivity of six antibodies in effusions of mesothelioma, adenocarcinoma and mesotheliosis: stepwise logistic regression analysis.
Anti-CEA, anti-vimentin, CAM5.2, BerEp4, Leu-M1 and anti-EMA were applied to effusions from 36 mesotheliomas, 53 adenocarcinomas and 24 reactive mesothelial proliferations. Stepwise logistic regression analysis selected three criteria of major importance for distinguishing between adenocarcinoma and mesothelioma: BerEp4, CEA and EMA accentuated at the cell membrane (mEMA), these three being of similar diagnostic value. The pattern BerEp4-, CEA- and mEMA+ was fully predictive for mesothelioma (sensitivity 47%), whereas the opposite pattern was fully predictive for adenocarcinoma (sensitivity 80%). Only EMA seemed to distinguish between mesotheliosis and mesothelioma. Comparison of reactivity in cytological and histological material from the same mesotheliomas showed similar staining frequencies for CEA and CAM5.2, with some random variation for Leu-M1 and EMA, whereas vimentin and BerEp4 reactivity was more frequent in cytological specimens.
Dejmek
A
A
Department of Clinical Cytology and Pathology, Lund University, Malmö Academic Hospital, Sweden.
Hjerpe
A
A
D000230:Adenocarcinoma / Q000175:diagnosis / Q000276:immunology*; D000911:Antibodies, Monoclonal / Q000276:immunology; D000912:Antibodies, Neoplasm / Q000276:immunology*; D000918:Antibody Specificity; D000951:Antigens, Neoplasm; D000954:Antigens, Surface / Q000032:analysis / Q000276:immunology; D015415:Biomarkers; D014408:Biomarkers, Tumor / Q000032:analysis / Q000276:immunology*; D002272:Carcinoembryonic Antigen / Q000032:analysis / Q000276:immunology; D003937:Diagnosis, Differential; D004848:Epithelium / Q000276:immunology*; D006801:Humans; D006965:Hyperplasia; D007124:Immunoenzyme Techniques; D007633:Keratins / Q000032:analysis / Q000276:immunology; D016256:Lewis X Antigen; D016015:Logistic Models; D008175:Lung Neoplasms / Q000175:diagnosis / Q000276:immunology*; D008654:Mesothelioma / Q000175:diagnosis / Q000276:immunology*; D018396:Mucin-1 / Q000032:analysis / Q000276:immunology; D009363:Neoplasm Proteins / Q000032:analysis / Q000276:immunology*; D016066:Pleural Effusion, Malignant / Q000175:diagnosis* / Q000276:immunology; D012680:Sensitivity and Specificity; D014746:Vimentin / Q000032:analysis / Q000276:immunology
D000911:Antibodies, Monoclonal; D000912:Antibodies, Neoplasm; D000951:Antigens, Neoplasm; D000954:Antigens, Surface; C117805:Ber-EP4 monoclonal antibody; D015415:Biomarkers; D014408:Biomarkers, Tumor; C400901:CAM 5.2 antigen; D002272:Carcinoembryonic Antigen; C407642:Leu-M1 antigen; D016256:Lewis X Antigen; D018396:Mucin-1; D009363:Neoplasm Proteins; D014746:Vimentin; C115012:human epithelial antigen-125; D007633:Keratins